Terms: = Lung cancer AND FAS, FAS1, 355, ENSG00000026103, FASTM, APO-1, P25445, CD95, ALPS1A, TNFRSF6, APT1 AND Clinical Outcome
9 results:
1. Predictive value of unmethylated RASSF1A on disease progression in non-small cell lung cancer patients receiving pemetrexed-based chemotherapy.
Deng Q; Su B; Ji X; Fang Q; Zhou S; Zhou C
Cancer Biomark; 2020; 27(3):313-323. PubMed ID: 31839603
[TBL] [Abstract] [Full Text] [Related]
2. miR-193b availability is antagonized by LncRNA-SNHG7 for FAIM2-induced tumour progression in non-small cell lung cancer.
She K; Yan H; Huang J; Zhou H; He J
Cell Prolif; 2018 Feb; 51(1):. PubMed ID: 29131440
[TBL] [Abstract] [Full Text] [Related]
3. Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients.
Marquardt JU; Fischer K; Baus K; Kashyap A; Ma S; Krupp M; Linke M; Teufel A; Zechner U; Strand D; Thorgeirsson SS; Galle PR; Strand S
Hepatology; 2013 Sep; 58(3):1054-64. PubMed ID: 23526469
[TBL] [Abstract] [Full Text] [Related]
4. Clinicopathological significance of cathepsin D expression in non-small cell lung cancer is conditional on apoptosis-associated protein phenotype: an immunohistochemistry study.
Fan C; Lin X; Wang E
Tumour Biol; 2012 Aug; 33(4):1045-52. PubMed ID: 22302483
[TBL] [Abstract] [Full Text] [Related]
5. A polymorphic -844T/C in fasL promoter predicts survival and relapse in non-small cell lung cancer.
Sung WW; Wang YC; Cheng YW; Lee MC; Yeh KT; Wang L; Wang J; Chen CY; Lee H
Clin Cancer Res; 2011 Sep; 17(18):5991-9. PubMed ID: 21807637
[TBL] [Abstract] [Full Text] [Related]
6. Nuclear localized phosphorylated FADD induces cell proliferation and is associated with aggressive lung cancer.
Bhojani MS; Chen G; Ross BD; Beer DG; Rehemtulla A
Cell Cycle; 2005 Nov; 4(11):1478-81. PubMed ID: 16258269
[TBL] [Abstract] [Full Text] [Related]
7. Hypermethylation of the death-associated protein kinase promoter attenuates the sensitivity to TRAIL-induced apoptosis in human non-small cell lung cancer cells.
Tang X; Wu W; Sun SY; Wistuba II; Hong WK; Mao L
Mol Cancer Res; 2004 Dec; 2(12):685-91. PubMed ID: 15634757
[TBL] [Abstract] [Full Text] [Related]
8. fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of fas ligand tumor counterattack.
Donskov F; von der Maase H; Marcussen N; Hamilton-Dutoit S; Madsen HH; Jensen JJ; Hokland M
Clin Cancer Res; 2004 Dec; 10(23):7911-6. PubMed ID: 15585624
[TBL] [Abstract] [Full Text] [Related]
9. Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival.
Volm M; Koomägi R
Br J Cancer; 2000 May; 82(10):1747-54. PubMed ID: 10817513
[TBL] [Abstract] [Full Text] [Related]
